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Abstract
Background: With 16,005 new cases and 5,406 related deaths in 2005, France is particularly concerned by Head
and Neck (H&N) cancers. In addition to tobacco and alcohol, Human Papillomavirus (HPV) has been reported as a
risk factor for H&N cancers. The literature on the burden of these cancers in Europe is scarce. This study was
performed to assess the medical and economical burden of hospitalisations for H&N cancers in France.
Methods: The French national hospital database (PMSI), in which admissions to public and private hospitals are
recorded, was retrospectively analysed to assess the annual number of patients hospitalised for H&N cancers and
associated hospital costs from the healthcare payer perspective. ICD-10 codes (16 codes classified as oral cavity,
oropharynx, pharynx, salivary glands and larynx) were used to extract admissions for these cancers. Hospital stays,
chemotherapy and radiotherapy sessions were extracted to assess patients’ management. Costs of admissions were
obtained from French official tariffs.
Results: In 2007, there were 36 268 patients hospitalised for H&N cancers, of whom 81% were men, corresponding
to 60 200 hospital stays and 287 846 sessions of chemo- or radio-therapy. Oropharynx cancer was the most
frequent (28% of patients), followed by oral cavity cancer (25% of patients). The peak of frequency was observed in
the 55-59 years age group. Patients were mainly treated in medicine (48%) and surgery (23%) units. Mean annual
cost per patient ranged from €2 764 to €7 673 leading to a total hospital cost of €323 millions in 2007 (including
hospitalization and expensive drugs). With 26% of H&N cancers attributable to HPV infections, 9 430 patients were
hospitalized due to HPV-related H&N cancers, representing €138 million in 2007.
Conclusion: Even without taking into account the rehabilitation costs, the hospital burden of H&N cancers is
considerable.
Background
In Europe, head and neck cancer (H&N) accounted for
approximately 143 000 new cancers in 2007 and were
responsible of more than 68 000 deaths [1]. They have
broadly varying rates of incidence and mortality around
the world. In North America and Europe, tumours
usually arise from the oral cavity, oropharynx, or larynx,
whereas nasopharyngeal cancer is more common in the
Mediterranean countries and in the Far East. France is
particularly concerned by head and neck cancers [2].
With 16 005 new cases in 2005, they represented 3.8%
of all incident cancer cases. They are the fourth highest
incidence of cancers in men and the eleventh highest
incidence in women. In terms of mortality, 5 406 related
deaths occurred in 2005, including 82% in men. It repre-
sented 2.7% of annual cancer deaths and the tenth more
lethal cancer [3,4].
These cancers are more common in men and in peo-
ple over age 50. Head and neck cancer refers to a group
of cancers originating from the upper aerodigestive
tract, including oral cavity, oropharynx, pharynx other
than oropharynx (nasopharynx, hypopharynx), larynx,
salivary glands, and other sites located in the head and
neck area. Head and neck cancers are strongly asso-
ciated with environmental and lifestyle risk factors. Use
of tobacco is the largest risk factor for H&N cancers
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in the incidence of head and neck cancer has however
decreased, thanks to public health efforts at tobacco
control and reduction in the prevalence of cigarette
smoking. Alcohol consumption is frequently associated
with tobacco use as a co-factor in oncogenic risk, espe-
cially in oral cavity and hypopharynx cancers.
Moreover, numerous studies have highlighted the
increasing role of the sexually transmitted human papil-
lomavirus (HPV) in the incidence of H&N cancers. Con-
tribution of HPV in H&N cancers varies according to
tumour site location. Most HPV positive cancers occur
in the oropharynx [7], in particular tonsil and base of
the tongue. HPV could account for 33% to 72% of oro-
pharynx cancers [8,9]. Tonsillar cancers have been
reported to have the highest prevalence rate of HPV-
DNA (more than 50%) [10-12]. HPV positive rates are
lower in other localizations, ranging from 5 to 16% for
larynx [13,14], 24% in a report including hypopharynx
carcinomas in larynx [8,15] and 23.5% in oral cavity.
The wide variations in HPV prevalence which are
reported may depend on the HPV diagnostic methodol-
ogies, especially in earlier studies.
Treatment of head and neck cancer depends on the
initial localization of the tumor, on patient’s comorbidity
and on potential side effect of treatment. Surgical resec-
tion, radiotherapy, radiochemotherapy, induction
chemotherapy, radiobiotherapy (with anti epidermal-
growth-factor receptor (EGFR) like cetuximab and other
anti EGFR), are the therapeutic methods in locally
advanced cases, the most frequent mode of presentation
of H&N cancers. The overall prognosis remains poor. In
addition, patients frequentlys u f f e rf r o mo t h e rc o - m o r -
bidities. A number of advances in therapies for head
and neck cancers have been developed in the past sev-
eral years, including the availability of anti-EGFR agents,
induction chemotherapy, new microsurgical and recon-
structive surgery techniques or accelerated radiotherapy.
The economic impact of head and neck cancers is
poorly documented. The cost of illness has been esti-
mated for some specific countries, like the UK [16], the
USA [17], the Netherlands [18], Greece or Germany
[19], using various methodologies. Moreover, as these
cancers presented great variation in terms of localisation
and incidence rate worldwide, the use of economic esti-
mations performed in others countries may be hazar-
dous. In 2004, the French National Institute of Cancer
(Institut National du Cancer-INCa) has estimated that
the global direct medical costs related to cancer
amounted to 11 milliards euros (Md€), including 7 Md€
due to hospitalisation costs, whereas indirect costs due
to loss of productivity and premature death were esti-
mated at 17 Md€ [20].
The specific cost related to head and neck cancers in
France has however never been documented. The objec-
tive of the present study was to assess the annual num-
ber of patients hospitalised for head and neck cancers in
France and to estimate the economic burden associated
with their management.
Methods
Data sources
A retrospective analysis was performed using data
extracted from the French Medical Information System
(Programme de Médicalisation des Systèmes d’Informa-
tion - PMSI) for 2007 which covers all French public
and private hospitals, except military and psychiatric
hospitals. In fact, since 2004, all French hospitals has
adopted a prospective payment system based on case-
mix, called “Tarification à l’Activité”. Each hospital stay
resulted in the production of a standard discharge sum-
mary ("Résumé Standard de Sortie” RSS) following inpa-
tient conventional stays, day-hospital stays or sessions.
The RSS contains information on the nature of the
treatment and work-up (the examinations) carried out
during the stay, on the main diagnosis that led to the
hospital admission, on co-morbidities or possible com-
plications. Diagnoses are coded using the International
Classification of Diseases, 10
th revision (ICD-10) either
as primary, related, or significant associated diagnosis.
The RSS is then integrated into a Diagnosis Related
Group (DRG) used for classification of hospital stays.
All the hospital stays and sessions performed during a
specific year are summarized into standardized discharge
reports and collected in a national database called PMSI.
This database is the basis of hospitals funding, but also
allows to estimate various indicators by disease, like the
number of patients treated annually, the number of
stays per patient or the burden of the disease, with an
exhaustiveness close to 98% in 2007 [21].
The SAE database (’’Statistique Annuelle des Etablisse-
ments de santé’’) [22] relies on information collected
through an exhaustive and compulsory survey covering
all French hospitals. It was used to extract data on
radiotherapy sessions for private sector, as they are not
available in the PMSI database.
Since the introduction of a DRG type prospective per
case payment in 2004, a list of so-called expansive
drugs has been set. Conversely to other drugs whose
cost are included in the DRG tariff, drugs on the list
are reimbursed 100% to the hospital based on a
national reference reimbursement tariff and the EMI,
conditional to the adherence of prescription recom-
mendations. The FICHCOMP database contains the
expenses of drugs on the list, by drug and per stay (for
public hospitals only).
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Cases were extracted from the PMSI database using the
ICD-10 codes referring to head and neck cancers. They
were classified into five categories corresponding to five
localizations: oral cavity (including lip, tongue, gum,
floor of the mouth, palate, and mouth; coded as C00,
C02-06), salivary glands (including parotidis glands, sali-
vary glands; coded as C07-08), oropharynx (including
base of tongue tonsil, oropharynx; coded as C01, C09-
10), pharynx other than oropharynx (including rhino-
pharynx, pyriform sinus, hypopharynx, others; coded
C11-14) and larynx (coded as C32).
Number of stays
The annual number of stays was assessed after extrac-
tion of all hospital stays with one of the above-men-
tioned head and neck cancers as a primary diagnosis in
the hospital database. Since a single hospital stay may
include other ICD codes with head and neck cancers
coded as related or significant associated diagnosis (and
not primary diagnosis), a medical interpretation by a
PMSI specialist was required to assess whether the spe-
cific hospital stay had a direct link with the diagnoses of
interest. All medical stays were classified according to
the type of management: medical, surgical, exploration
or palliative care. Distinction was made between full
stays and one-day hospital setting (defined as hospitali-
zations of less than 48 hours). Diagnosis Related Groups
(DRG) were evaluated, as well as the length of stay for
full stays.
Number of chemotherapy and radiotherapy sessions
The number of sessions referred both to chemotherapy
and radiotherapy sessions. Data on chemotherapy ses-
sions were extracted from the PMSI database, by select-
ing all hospital stays with a primary diagnosis coded as
Z51.1 (’’Chemotherapy session of neoplasm’’)a n da n
associated or a related diagnosis coded as a head and
neck cancer. In the same way, data on radiotherapy ses-
sions were extracted using the Z51.0 code (’’Radiother-
apy session’’) as primary diagnosis. It only concerned
the radiotherapy sessions performed in the public sector
(radiotherapy sessions performed in the private sector
are usually not reported in the PMSI database). The
SAE database was used to estimate the overall annual
number of radiotherapy sessions performed in public
and private hospitals in 2007 and to calculate the ratio
between public and private radiotherapy sessions. The
annual number of radiotherapy sessions performed in
the private sector was then estimated by applying the
ratio to the number of radiotherapy sessions for head
and neck cancers retrieved in the PMSI database in the
public sector.
Number of patients
Since a patient may have several hospital stays or ses-
sions during a year, the number of patients hospitalized
at least once in 2007 for head and neck cancers was
obtained by linking all hospital stays and sessions, based
on patient’s identification number. This number is built
using the patient’s social security number, date of birth
and gender. After anonymisation, data are sent to the
regional agency of hospitalization ("Agence Régionale
d’Hospitalisation - ARH”). This number allows linking
all hospital stays that occurred in public and private sec-
tors in 2007 by patient (except for radiotherapy session
performed in the private sector). It is then possible to
estimate the total number of head and neck cancer
patients that were hospitalized at least once in 2007, by
sex and age group. In 2007, respectively 98% and 87% of
all hospital stays and sessions were successfully chained,
meaning that the total number of patients with radio-
therapy or chemotherapy sessions was slightly
underestimated.
Economic evaluation
Costs were considered from the healthcare payer per-
spective. It included hospitalization costs and expenses
of innovative drugs, related to public and private sectors.
Ambulatory costs and indirect costs related to produc-
tivity loss were not considered in the main analysis.
Hospital costs were calculated using the official 2008
diagnosis related group (DRG) tariffs for public hospitals
(that were the tariffs available when the analysis was
performed). Tariffs included nursing care, treatments,
drugs, accommodation and investment costs for hospita-
lized patients. For public hospitals, it also covers medical
and technical acts. For private hospitals, costs were esti-
mated using the official 2008 DRG tariffs for private
hospitals to which physician’s fees were added as they
are not included in private DRG tariffs and are reim-
bursed on a fee-for-service basis (source: ENCC 2006)
[23]. Since no data are available on the cost for radio-
therapy session in the private setting, its cost was esti-
mated using those calculated for the public sector. Costs
are presented as mean annual cost per patient (based on
patients for whom data were firmly linked) and total
cost per year (for all patients hospitalized in 2007) and
were expressed by gender, cancer localization, type of
care and sector (public or private).
The economic impact of expensive drugs was esti-
mated by linking the chemotherapy sessions or stays for
palliative care extracted from the PMSI database with
the FICHCOMP database. It allows evaluating the pro-
portion of these stays including the administration of an
expensive drug, as well as the cost of expensive drugs.
Since the FICHCOMP database was accessible for the
Lacau St Guily et al. Head & Neck Oncology 2010, 2:22
http://www.headandneckoncology.org/content/2/1/22
Page 3 of 8first time for the year 2008, this was performed by using
H&N cancers related stays of 2008 (by using the same
methodology than in 2007).
The economic burden of H&N cancers attributable to
HPV infection was estimated by using the specific pre-
valence of HPV infection by localization (data extracted
from the international published literature, no available
data for salivary glands and pharynx cancers other than
oropharynx).
Results
Table 1 gives the number of hospital stays and sessions
and the number of patients hospitalized for head and
neck cancer in France in 2007.
Number of patients
In 2007, 36 268 patients were hospitalized for head and
neck cancer in France. The most frequent localization of
cancer was the oropharynx (n = 12 232), followed by the
oral cavity (n = 10 786), the pharynx other than orophar-
ynx (n = 9 718), the larynx (n = 9 516) and the salivary
glands (n = 1 831) (Table 1). Most of the patients were
males (81%), but the proportion of men varied from 61%
for salivary glands cancer to 88% for larynx cancer. For
most H&N cancers, incidence increased with age until
the group age of 55-59 years and then decreased. The
scheme is slightly different for salivary gland cancer
whose incidence is increasing with age (Figure 1).
Number of stays and sessions
In 2007, the management of head and neck cancers was
responsible for 60 200 hospital stays and 287 846 che-
motherapy or radiotherapy sessions. For stays, the most
common type of management was medical care, which
represented 48% of stays, especially for the management
of patients with cancer of oropharynx, pharynx or lar-
ynx. 80% of these stays were performed in the public
sector and the mean length of stay was 6 days. 6% of all
medical stays were for chemotherapy. Surgery concerned
23% of stays and mainly concerned patients with cancer
of oral cavity or oropharynx. 70% of these stays were
seen in the public sector. Stays for exploration repre-
sented 22% of stays, were mainly performed in day-hos-
pital setting and both concerned public and private
sector. Palliative care concerned 8% of stays, 80% of
them were performed in public sector and their mean
length of stay was 16 days. The figure 2 presented the
part of each type of management by cancer localization.
Among the 287 846 sessions extracted, 211 131 ses-
sions (73%) were for radiotherapy. 83% of the sessions
concerned men. The number of sessions by cancer loca-
lization is presented in table 1. Patients received an
average of 18 sessions of chemotherapy or radiotherapy
per year. Seventy-nine percent of radiotherapy sessions
were made in public setting.
Hospital cost
Table 2 gives the mean hospital cost per patient and the
total annual cost per localization and per category of
cost.
The mean annual cost of hospitalization reached €7
842 per patient with head and neck cancers. However, a
great heterogeneity was observed between public and
private sector, cancer localization and type of manage-
ment, as presented in table 2. For example, the mean
annual cost per patient with H&N cancers varied from €
6 151 to € 7 673 in public hospitals, whereas it varied
from €27 6 4t o€3 562 in the private sector. The annual
cost of hospitalization was higher in men than in
women, respectively equal at 8 038 € and 6 982 € on
average. The type of management also influenced hospi-
talization costs: they were higher if the primary diagno-
sis was surgery or palliative care than for chemotherapy
or radiotherapy. In 2007, total hospitalization cost for
head and neck cancers in France amounted to €284
millions.
An expensive drug was administered in 53% of ses-
sions for chemotherapy and 8% of stays for palliative
Table 1 Annual number of patients, hospital stays and sessions in 2007
Number of stays (% of PD) Number of sessions Number of patients* Men (%)
Public Private Global
Oral cavity 15,093 (70%) 57 294 7,685 3,803 10,786 75
Salivary glands 1,884 (73%) 11 841 1,218 704 1,831 61
Oropharynx 16,519 (60%) 99 618 8,558 4,813 12,232 82
Pharynx 14,358 (56%) 70 753 6,981 3,586 9,718 87
Larynx 12,346 (72%) 48 339 6,714 3,557 9,516 88
Total 60,200 (57%) 287 846 25,987 14,788 36,268 81
* As some patients may have been hospitalized for several cancers, the total number of patients is not equal to the sum of the number of patients by
localization. The global number of patients is also not equal to the sum of patient treated in public and private sector, as some patients were treated in both
sector.
PD = Primary Diagnosis
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by the administration of expensive drug varied accord-
ing cancer localization, ranging from 46% for
hypopharynx to 89% for lip. Most of these sessions or
stays concerned men (85%). The global amount of
expensive drug reached 38 929 041 €. Total hospital
cost, including hospitalization and expensive drugs, then
amounted to 323 millions € in 2007.
Burden of HPV-related H&N cancers in 2007
Twenty-six percent of head and neck cancers are attri-
butable to HPV infections [8], the overall HPV preva-
lence varying from 33% to 72% for oropharynx, 23.5%
for oral cavity and to 5 to 24% for larynx (no published
available data regarding the prevalence of HPV in sali-
vary glands and pharynx other than oropharynx). Using
t h e s ep r e v a l e n c ed a t a ,t h ea n n u a ln u m b e ro fp a t i e n t s
hospitalized due to HPV-related H&N cancers was esti-
mated to be 9 430. The annual burden of HPV-related
cancer reached €138 million in 2007 (Table 2).
Discussion
This survey was designed to estimate the annual num-
ber of patients hospitalized for head and neck cancers in
France in 2007 and their related management costs. The
study showed that the impact of head and neck cancers
was important, as, in 2007 there were 36 268 patients
hospitalised, corresponding to 60 200 hospital stays and
287 846 sessions of chemo- or radiotherapy. Orophar-
ynx cancer was the most frequent (28% of patients), fol-
lowed by oral cavity cancer (25% of patients). The study
showed that annual hospital cost, (including hospitalisa-
tion and expensive drugs) of these patients appeared to
be very high, close to 306 millions €. Men are particu-
larly concerned by H&N cancers, as they represented
81% of all patients treated and 83% of all expenses (254
millions €).
Figure 1 Age distribution of patients with head and neck cancers.
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Figure 2 Hospital stays distribution per category of care.
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presented a high exhaustiveness and a high level of
quality. As discharge reports are the basis of hospitals
funding and their reporting is mandatory, the PMSI
database contained more than 98% of all public and pri-
vate hospital stays in 2007, then limiting the sampling
errors. Moreover, as all diagnoses are coded using the
ICD-10 classification, all discharge reports are standar-
dized, allowing to perform extraction of stays by disease.
Coding errors is expected to be rare as this database
constitutes the prospective financial system based on
hospital activity, and since financial resources are
directly related to the coded information. Coding quality
in the PMSI is expected to be high and is guaranteed by
controls performed annually in each hospital. The PMSI
database is then widely used to provide relevant infor-
mation on the burden of hospitalizations in France
[24,25] and it can be used to evaluate the annual burden
of hospitalization of head and neck cancers in France.
The PMSI database also presented few limitations.
First, it was not possible to evaluate with precision the
number of sessions of radiotherapy performed in the
private setting, as they are not included in the PMSI
database. This number was calculated using the SAE
database, after the application of the ratio between
public and private radiotherapy sessions. The calcula-
tion of the ratio was however not specific to head and
neck cancers, but global for all cancers. Moreover, the
global number of patients hospitalized for head and
neck cancers in 2007 may be underestimated, as it was
not possible to link the radiotherapy sessions per-
formed in the private sectors with the stays from the
PMSI database.
This administrative database only concerned patient
who are hospitalized at least one time per year. Patients
with head and neck cancers managed exclusively in an
outpatient setting are not included in the present analy-
sis, leading therefore to a potential underestimation of
the total annual number of cases of H&N cancers.
Moreover, despite presence of an identification number,
it is not possible to distinguish incident cases (newly
diagnosed patients, in active cancer treatment, with
expensive cancer treatment cost) from the other cases
(patients in maintenance treatment, with less expensive
treatment cost). Thus, the estimated mean cost per hos-
pitalized patient reflects the average cost of management
of all cases admitted to hospital (prevalent cases). This
may be lower than the cost per patient of management
of new cases only, as shown by van Agthoven et al. (17),
who demonstrated that the cost of H&N cancers was €
21 858 for the two years following diagnosis and it
decreased to 423 € during the 10 years of follow-up.
Our estimations are similar with those for European
countries: the total cost to society from head and neck
cancers ranged from € 5.5 millions in Greece (for 650
cases per year) to € 893 millions in Germany. It is how-
ever difficult to make a comparison, given the differ-
ences in terms of incidence and structure of the
Sickness Fund.
The use of PMSI database leads to underestimation of
the burden of disease, as it is restricted to hospitaliza-
tion costs. Other categories of cost, like expensive drug,
indirect or outpatient costs were estimated by using
other sources of data. Cost of expensive and innovative
drugs, like cetuximab or docetaxel, was estimated using
the FICHCOMP database from the year 2008 (as this
database was not yet available in 2007). It was also not
possible to directly evaluate the indirect costs related to
loss of productivity. In France, the valuation of indirect
costs used the budgetary approach which relates to the
Table 2 Mean hospital cost per patient and total annual costs per localization and per category of cost
(hospitalization, expensive drugs, outpatient and indirect costs) and from a payer perspective
Mean hospital
cost per
patient (€)
Total annual cost (all patients) from payer perspective** (€)
Public Private Hospital cost Expensive
drugs
Indirect
cost
Outpatient
cost
Total** HPV positive
cancer
HPV related
cost*
Oral cavity 7,673 3,054 71°558°167 7 727 519 18 395 395 33 013 172 130 694 253 23.5% 30 713 149
Salivary
glands
6,151 2,929 9°728°585 991 317 2 063 391 4 488 257 17 271 550 - -
Oropharynx 7,575 3,562 83°415°630 14 114 364 22 708 632 38 483 581 158 722 207 33 to 72% 52 378 328 to
114 279 989
Pharynx 7,580 3,468 66°449°315 10 907 202 17 570 038 30 656 216 125 582 771 - -
Larynx 6,355 2,764 53°277°788 5 156 119 15 238 397 24 579 567 98 251 871 5 to 24% 4 912 594 to
23 645 249
Total 8,730 3,576 284°429°484 38 929 041 75 975 853 131 220 792 530 555 170 26% 137 944 344
* HPV related cost = prevalence × (hospital cost + expensive drugs + indirect cost + outpatient cost)
** Rehabilitation costs are not included in this estimate
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monetary compensation served to patients to offset par-
tially their loss of income. This amounted to €46.2 per
day of sick leave (calculated by dividing the total
amount of compensation paid in Year 2007 by the total
number of sick leave days (data provided by the
National Health Accounts)). In the present study, an
estimation of indirect costs can be calculated using
results from the INCa report 2007 [20], which showed
that the proportion of patients who stop working
because of head and neck cancers was 91% and the
mean length of sick leave was 120 days. According to
these assumptions, indirect costs amounted to about
€76 millions. These indirect costs only represent the
part supported by Sickness Fund. From a societal per-
spective, other indirect costs, due to premature death,
w o u l da l s oh a v et ob ec o n s i d e r e d .M o r e o v e r ,e x c e p tf o r
patients requiring a hospitalization, cost of management
of side-effects of treatment for H&N cancers, like dys-
phagia or mucositis, which are usually managed in
ambulatory care, were not evaluated in the present
study. For example, the cost of treatment of dysphagia
was evaluated at $153 to $710 [26], whereas it reached €
3 480 to 4 764 per episode of mucositis [27]. Moreover,
Penel et al [28] estimated that 31% of patients presented
nosocomial infections or pneumonia following H&N
surgery, inducing an extra-cost of management esti-
mated at respectively 16 000 and 17 000 €, as compared
to patients without nosocomial infections or pneumonia.
This extra-cost was not included in the present analysis,
because of the risk of double-counting process (as many
nosocomial infections are managed in hospital for H&N
patients). Concerning the outpatient costs, as no specific
data on outpatient management for head and neck can-
cers were available to our knowledge, we used estimates
of the management costs for H&N tumours, published
by Weill et al [29], reporting the frequency and cost of
30 long-term disorders in France based on an analysis
of national health insurance reimbursement databases.
We retrieved from this study that the outpatient costs
(including visits, drugs, exams, transportation) repre-
sented 31.6% of global cost in patients suffering from
head and neck cancers. In the present study, the annual
outpatient cost can then be estimated at €131 million.
The total cost of management of head and neck cancers,
from a Payer perspective, then amounted to €531 mil-
lion per year, including hospitalisation, expensive drugs,
outpatient and indirect costs. Some costs, like rehabilita-
tion cost, were not estimated as no data are available.
For head and neck cancers patients who had devastating
physical and functional changes, rehabilitation care plays
an important role on restoring function and assisting
t h ep a t i e n tt oa c h i e v ea na c c e p t a b l eq u a l i t yo fl i f e .I t
then appeared important to evaluate their cost.
Given the considerable burden of disease induced by
head and neck cancers, it appears important to identify
strategies allowing to reduce costs and to save money.
Nevertheless, at this time, there is no data indicating if
prevention (reduction of alcohol and smoking, HPV
incidence), screening, targeted treatment will allow to
reduce the costs in the future. The cost-benefit of these
strategies may be evaluated in the specific context of
head and neck cancers.
There is a growing evidence for a causal role for HPV
(mainly HPV 16) in a subset of H&N cancers [11]. The
proportion of HPV-positive oral cancers has significantly
increased over the past decades, in parallel with a
decline in HPV-negative cancers [10,30]. HPV vaccina-
tion has demonstrated a high prophylactic efficacy
against HPV 16 and 18 related pre-cancerous lesions of
the cervix, vulvar and vaginal. One can expect that HPV
vaccination might extend protection against other can-
cers associated to HPV 16 and 18. These study’sd a t a
could provide useful information for decision-makers in
order to assess the potential additional effect of the
HPV vaccination on H&N cancers.
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